Baidu
map

Nature:线粒体钙稳态机制被揭密,有望成为心脏疾病治疗新靶点

2017-04-29 MedSci MedSci原创

科学界一致认为线粒体的钙离子输送量是心脏工作强度,或是由能量带动的心脏跳动强度的重要衡量指标。天普大学Lewis Katz医学院(LKSOM)和其他机构的科学家们已经鉴定了在压力条件下的线粒体钙离子途径。但是他们仍有一个疑问:线粒体的钙离子稳态是否也是正常心脏功能的必要条件?如今,利用新研制出的突变老鼠模型,John W. Elrod副教授的科学家团队证实了Slc8b1基因(线粒体钠钙交换体)或称

科学界一致认为线粒体的钙离子输送量是心脏工作强度,或是由能量带动的心脏跳动强度的重要衡量指标。天普大学Lewis Katz医学院(LKSOM)和其他机构的科学家们已经鉴定了在压力条件下的线粒体钙离子途径。但是他们仍有一个疑问:线粒体的钙离子稳态是否也是正常心脏功能的必要条件?

如今,利用新研制出的突变老鼠模型,John W. Elrod副教授的科学家团队证实了Slc8b1基因(线粒体钠钙交换体)或称作mitochondrial Na+/Ca2+ exchanger,NCLX,能够影响心脏的正常功能,缺失NCLX动物多会立即死亡,仅13%动物能存活两周。这项首次使用活体动物进行线粒体钙离子流出实验的研究成果被报道于4月26日的《Nature》杂志。该研究证实了线粒体中钙离子的流失严重影响心脏功能,代表着一个强有力的改善心脏病的治疗方法。

线粒体钙离子交换,即钙离子在负责能量生产的细胞器中流进流出,这种活动对细胞的死亡和需用能量推进的信号通路都是最基本的要素。“在前期的实验中我们发现,抑制钙离子的摄取,能导致心脏压力反应的丧失,”Elrod解释道。“我们发现,在压力胁迫下,心脏线粒体需要摄取钙离子来加强心动力,然而过多的钙离子摄取也会诱发心脏细胞死亡。如今在没有压力干扰的情况下,动物正常心脏功能实验结果,暗示了一条独立的、钙离子信号自我平衡的基础机制。”

为了规避其他可能存在的线粒体钙离子吸收途径,Elrod和同事们构建了一种条件型基因敲除小鼠模型,NCLX基因仅在用三苯氧胺(tamoxifen)药物处理后方被敲除,这使得基因敲除小鼠可以活到成年。“通过删掉NCLX,我们能确定线粒体外排的重要性,”Elrod说。

当成年小鼠的NCLX突然关闭后,小鼠立即死于心脏衰竭。检查死亡小鼠的心肌细胞,发现了肿胀和功能障碍的线粒体,并且线粒体通透性转换孔(mitochondrial permeability transition pore ,MPTP)被激活了,该指标曾被证实是钙离子超载导致细胞死亡的标志。

通过基因操纵抑制MPTP的活化,能拯救NCLX基因敲除型小鼠的猝死症状,维持了心脏内部线粒体钙离子交换的自然平衡。

Elrod和同事们使用基因技术手段,还探索了NCLX过表达的情况。正如预期所料,过表达NCLX增加了线粒体钙离子的外流,防止了心脏病发作小鼠的细胞死亡现象,并通过减少活性氧的产生和限制心肌细胞纤维化(组织硬化)和死亡起到了阻止心力衰竭的作用。

“靶向NCLX的心肌细胞死亡挽救实验,被证明是有效的,”Elrod博士说。“我们的研究结果表明,细胞内线粒体钙离子疏导是一种有希望的治疗靶点,很有可能缓解心脏功能性疾病的不可逆转的严重症状。”
 
原始出处:


Luongo TS, Lambert JP, Gross P, Nwokedi M, Lombardi AA, Shanmughapriya S, Carpenter AC, Kolmetzky D, Gao E, van Berlo JH, Tsai EJ, Molkentin JD, Chen X, Madesh M, Houser SR, Elrod JW.The mitochondrial Na+/Ca2+ exchanger is essential for Ca2+ homeostasis and viability. Nature. 2017 Apr 26. doi: 10.1038/nature22082  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982762, encodeId=be781982e6216, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Oct 07 17:43:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881980, encodeId=35ea188198062, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 19 23:43:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646704, encodeId=69f91646e043b, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Fri Jul 14 09:43:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288210, encodeId=7c43128821000, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395359, encodeId=28e01395359d0, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517365, encodeId=2dc2151e365e0, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191872, encodeId=7fc61918e26e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Sat Apr 29 17:24:34 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1982762, encodeId=be781982e6216, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Oct 07 17:43:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881980, encodeId=35ea188198062, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 19 23:43:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646704, encodeId=69f91646e043b, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Fri Jul 14 09:43:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288210, encodeId=7c43128821000, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395359, encodeId=28e01395359d0, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517365, encodeId=2dc2151e365e0, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191872, encodeId=7fc61918e26e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Sat Apr 29 17:24:34 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-07-19 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1982762, encodeId=be781982e6216, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Oct 07 17:43:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881980, encodeId=35ea188198062, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 19 23:43:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646704, encodeId=69f91646e043b, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Fri Jul 14 09:43:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288210, encodeId=7c43128821000, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395359, encodeId=28e01395359d0, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517365, encodeId=2dc2151e365e0, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191872, encodeId=7fc61918e26e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Sat Apr 29 17:24:34 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-07-14 changfy
  4. [GetPortalCommentsPageByObjectIdResponse(id=1982762, encodeId=be781982e6216, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Oct 07 17:43:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881980, encodeId=35ea188198062, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 19 23:43:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646704, encodeId=69f91646e043b, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Fri Jul 14 09:43:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288210, encodeId=7c43128821000, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395359, encodeId=28e01395359d0, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517365, encodeId=2dc2151e365e0, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191872, encodeId=7fc61918e26e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Sat Apr 29 17:24:34 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-05-01 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1982762, encodeId=be781982e6216, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Oct 07 17:43:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881980, encodeId=35ea188198062, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 19 23:43:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646704, encodeId=69f91646e043b, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Fri Jul 14 09:43:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288210, encodeId=7c43128821000, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395359, encodeId=28e01395359d0, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517365, encodeId=2dc2151e365e0, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191872, encodeId=7fc61918e26e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Sat Apr 29 17:24:34 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1982762, encodeId=be781982e6216, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Oct 07 17:43:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881980, encodeId=35ea188198062, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 19 23:43:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646704, encodeId=69f91646e043b, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Fri Jul 14 09:43:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288210, encodeId=7c43128821000, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395359, encodeId=28e01395359d0, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517365, encodeId=2dc2151e365e0, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191872, encodeId=7fc61918e26e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Sat Apr 29 17:24:34 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1982762, encodeId=be781982e6216, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sat Oct 07 17:43:00 CST 2017, time=2017-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881980, encodeId=35ea188198062, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jul 19 23:43:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646704, encodeId=69f91646e043b, content=<a href='/topic/show?id=4478e5315e1' target=_blank style='color:#2F92EE;'>#稳态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75315, encryptionId=4478e5315e1, topicName=稳态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ebc23344390, createdName=changfy, createdTime=Fri Jul 14 09:43:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288210, encodeId=7c43128821000, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395359, encodeId=28e01395359d0, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517365, encodeId=2dc2151e365e0, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Mon May 01 04:43:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191872, encodeId=7fc61918e26e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xjZ9qh3bhXrJtUlmycKGfQKPuADVZQsdNAQj5IrHHlzbGsDwScictBgogYRk8KhicpgEKwTEfOHgqw/0, createdBy=bc931611963, createdName=jin321, createdTime=Sat Apr 29 17:24:34 CST 2017, time=2017-04-29, status=1, ipAttribution=)]
    2017-04-29 jin321

    学习

    0

相关资讯

Dev Cell:清华大学俞立研究组发现能量匮乏诱导自噬发生的分子机制

近日,国际著名学术杂志《Cell》子刊《Developmental Cell》杂志在线发表了清华大学医学院俞立研究组题为“线粒体Snf1-Mec1-Atg1复合物通过调控线粒体呼吸介导能量匮乏诱导的细胞自噬”(Formation of a Snf1-Mec1-Atg1 Module?on Mitochondria Governs Energy Deprivation-Induced Autopha

Neurobiol Aging:孔庆鹏课题组揭示长寿老人能量代谢状况优于普通老人的机制

长寿老人(特别是百岁老人)往往能逃脱或延缓常见衰老相关疾病的困扰,其后代发生老年疾病的概率也要显着低于一般人群。因此,健康长寿老人及其后代往往被视作健康衰老的理想模型,基于该模型深入解析其健康长寿的遗传机理,将可能为老年疾病的防治和干预提供全新的视角和机遇。中国科学院昆明动物研究所孔庆鹏课题组与海南医学院教授蔡望伟实验室的前期合作研究发现:长寿老人的能量代谢状况要显着优于普通老年人群(He et

Crit Care Med:脓毒症的生存改善与线粒体钙摄取减少有关!

近期,一项发表在杂志Crit Care Med上的研究旨在评估脓毒症期间的预后,心脏线粒体钙摄取变化与心脏生物能量状态之间的关系。此项研究的对象为雄性成年Wistar大鼠。通过腹腔注射粪便诱导大鼠脓毒症。假手术的动物作为对照组。使用共聚焦显微镜研究24小时败血症后分离的心肌细胞的功能和生物能量参数。使用电子显微镜评估线粒体和肌质网中的结构变化。通过超声心动图评估心脏对多巴酚丁胺的功能反应。此项研究

科学家披露“三亲”婴儿遗传细节

当一个美国生育诊所于去年透露,他们使用一项把三个人的脱氧核糖核酸(DNA)混合在一起的有争议技术创造出一名男婴时,科学家很快便发出了警告。一些人基于伦理道德对此提出反对,而另一些人则质疑由美国新希望生殖医学中心张进主持的这项研究的科学性。如今,经过几个月的激烈辩论和猜测,张进的团队提供了关于首个细胞核移植“三亲”婴儿的一些细节,相关论文发表在4月3日的生殖生物医学在线上。科学家说,目前这名婴儿健康

Nat Med:丙酮酸激酶M2激活可减缓糖尿病肾小球病变和线粒体功能障碍的进展!

因此,PKM2激活可能防止DN,通过增强葡萄糖代谢通路,抑制毒性葡萄糖代谢产物,并且诱导线粒体生物合成以恢复线粒体功能。

Cell Death Dis:王涛实验室发现PINK1的自磷酸化修饰在线粒体质量监控中起重要作用

作为细胞的能量工厂,线粒体对于维持细胞的正常生理功能十分重要。一系列外界环境因素的干扰或者内部遗传基因的突变造成线粒体损伤,损伤的线粒体若不能及时清除会引起许多种疾病的发生,其中就包括帕金森氏综合症,第二常见的神经退行性疾病。早期的研究报道帕金森氏综合症致病基因pink1和parkin的突变会引起功能缺陷线粒体在细胞中的滞留,大量形态瓦解和功能丧失线粒体释放促凋亡因子,最终造成细胞死亡,因此PIN

Baidu
map
Baidu
map
Baidu
map